Abilify: Atypical Antipsychotic for Symptom Control and Stability
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.77 | $46.44 (0%) | 🛒 Add to cart |
| 90 | $0.67 | $69.66 $60.20 (14%) | 🛒 Add to cart |
| 180 | $0.56 | $139.32 $101.48 (27%) | 🛒 Add to cart |
| 270 | $0.53 | $208.98 $142.76 (32%) | 🛒 Add to cart |
| 360 | $0.51
Best per pill | $278.64 $184.04 (34%) | 🛒 Add to cart |
| Product dosage: 15mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.32 | $39.56 (0%) | 🛒 Add to cart |
| 60 | $0.93 | $79.12 $55.90 (29%) | 🛒 Add to cart |
| 90 | $0.80 | $118.68 $72.24 (39%) | 🛒 Add to cart |
| 120 | $0.73 | $158.24 $87.72 (45%) | 🛒 Add to cart |
| 180 | $0.67 | $237.36 $121.26 (49%) | 🛒 Add to cart |
| 270 | $0.63 | $356.04 $170.28 (52%) | 🛒 Add to cart |
| 360 | $0.60
Best per pill | $474.72 $217.58 (54%) | 🛒 Add to cart |
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.12 | $63.64 (0%) | 🛒 Add to cart |
| 60 | $1.50 | $127.28 $90.30 (29%) | 🛒 Add to cart |
| 90 | $1.30 | $190.92 $116.96 (39%) | 🛒 Add to cart |
| 120 | $1.19 | $254.56 $142.76 (44%) | 🛒 Add to cart |
| 180 | $1.09 | $381.84 $196.08 (49%) | 🛒 Add to cart |
| 270 | $1.02 | $572.76 $276.06 (52%) | 🛒 Add to cart |
| 360 | $0.99
Best per pill | $763.68 $355.18 (53%) | 🛒 Add to cart |
Synonyms | |||
Abilify (aripiprazole) is an atypical antipsychotic medication indicated for the treatment of several psychiatric conditions. It functions as a partial dopamine agonist, which allows it to modulate dopamine activity rather than simply blocking it, offering a unique mechanism of action among its class. This profile provides a detailed, evidence-based overview of its clinical use, pharmacological properties, and essential safety information for healthcare professionals and informed patients. It is critical to use this medication only under the direct supervision of a qualified prescriber.
Features
- Active Ingredient: Aripiprazole
- Drug Class: Atypical Antipsychotic (Second-Generation Antipsychotic)
- Mechanism of Action: Functions as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptors
- Available Formulations: Oral tablets, orally disintegrating tablets, oral solution, and extended-release intramuscular injection (Abilify Maintena)
- Bioavailability: Oral bioavailability is approximately 87%
- Half-life: Approximately 75 hours (aripiprazole) and 94 hours (its active metabolite, dehydro-aripiprazole)
- Metabolism: Primarily hepatically metabolized via CYP3A4 and CYP2D6 enzymes
Benefits
- Provides effective control of positive symptoms (e.g., hallucinations, delusions) and negative symptoms (e.g., social withdrawal, apathy) associated with schizophrenia.
- Offers stabilization of acute manic and mixed episodes in bipolar I disorder, both as monotherapy and as an adjunct to lithium or valproate.
- Used as an adjunctive treatment to antidepressants for Major Depressive Disorder (MDD), enhancing therapeutic response.
- Helps in the management of irritability associated with autistic disorder in pediatric patients.
- Can be used for the maintenance treatment of bipolar I disorder to delay the time to relapse of mood episodes.
- The availability of a long-acting injectable (LAI) formulation improves adherence and provides consistent drug delivery.
Common use
Abilify is FDA-approved for the treatment of schizophrenia in adults and adolescents aged 13 years and older. It is also approved for the acute and maintenance treatment of manic and mixed episodes associated with bipolar I disorder in adults and pediatric patients aged 10 years and older, both as monotherapy and as an adjunct to lithium or valproate. Furthermore, it is indicated as an adjunctive therapy to antidepressants for Major Depressive Disorder (MDD) in adults. Additional approved uses include the treatment of irritability associated with autistic disorder in pediatric patients aged 6 to 17 years, and for the treatment of Tourette’s disorder in pediatric patients aged 6 to 18 years. Off-label uses may exist but should only be considered based on a thorough risk-benefit assessment by a treating physician.
Dosage and direction
Dosage must be individualized based on the specific indication, patient response, and tolerability. For schizophrenia in adults, the recommended starting dose is 10-15 mg once daily, with a target dose range of 10-30 mg daily. For bipolar mania, the starting dose is usually 15 mg once daily, which can be increased to a maximum of 30 mg daily. As adjunctive treatment for MDD, the starting dose is 2-5 mg daily, with a usual dose range of 2-15 mg daily. For the injectable formulation (Abilify Maintena), the initiation regimen includes overlapping oral supplementation. Administration should be with or without food. Dosage adjustments are necessary in patients who are known CYP2D6 poor metabolizers or when co-administered with CYP3A4 inhibitors or inducers. The exact dosing schedule and titration must be strictly determined by the prescribing clinician.
Precautions
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death; Abilify is not approved for this use. There is an increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults taking antidepressants; patients should be monitored closely for clinical worsening and emergence of suicidal thoughts. Use may be associated with orthostatic hypotension and syncope, particularly during initial dose titration. Caution is advised in patients with known cardiovascular disease, cerebrovascular disease, or conditions that would predispose them to hypotension. Abilify may cause potential cognitive and motor impairment; patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain the medication does not affect them adversely. Regular monitoring of weight, blood glucose, and lipid levels is recommended due to the potential for metabolic changes.
Contraindications
Abilify is contraindicated in patients with a known hypersensitivity to aripiprazole or any component of the formulation. Hypersensitivity reactions, including anaphylaxis, angioedema, and urticaria, have been reported.
Possible side effect
Common adverse reactions (≥10%) include akathisia, constipation, dizziness, insomnia, nausea, restlessness, and vomiting. Other important side effects include weight gain, somnolence, blurred vision, fatigue, and increased salivation. Extrapyramidal symptoms (EPS), such as tremor, rigidity, and bradykinesia, can occur. There is a risk of tardive dyskinesia, neuroleptic malignant syndrome (NMS), hyperglycemia and diabetes mellitus, dyslipidemia, and weight gain. Some patients may experience pathological gambling or other compulsive behaviors. This is not a complete list of all possible side effects.
Drug interaction
Aripiprazole is primarily metabolized by CYP3A4 and CYP2D6. Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) and strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine) will increase aripiprazole concentrations; dose reduction of Abilify is recommended. Conversely, strong CYP3A4 inducers (e.g., carbamazepine, rifampin, St. John’s Wort) will decrease aripiprazole concentrations and may require a dose increase. Due to its alpha1-adrenergic antagonism, Abilify may enhance the effects of certain antihypertensive drugs and increase the risk of orthostatic hypotension. Caution is advised when used with other CNS depressants (e.g., alcohol, benzodiazepines, opioids) due to additive sedative effects.
Missed dose
If a dose of oral Abilify is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be resumed. Patients should not take a double dose to make up for a missed one. For patients on the long-acting injectable formulation (Abilify Maintena), it is critical to adhere to the scheduled injection appointments. If an injection is missed, the prescribing physician should be contacted immediately for guidance on re-initiation, which may require supplemental oral dosing.
Overdose
In case of suspected overdose, immediate medical attention should be sought. Supportive measures should be instituted, with an emphasis on maintaining an adequate airway, oxygenation, and ventilation. Continuous cardiac monitoring is recommended. Symptoms of overdose may include somnolence, vomiting, agitation, aggression, confusion, tremors, tachycardia, hypotension, and seizures. There is no specific antidote for aripiprazole overdose. Management involves gastric lavage (if presented early) and administration of activated charcoal. Due to the long half-life of aripiprazole, prolonged monitoring and supportive care are necessary.
Storage
Store Abilify tablets, orally disintegrating tablets, and the oral solution at room temperature, between 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C to 30°C (59°F to 86°F). The oral solution should be stored in the original bottle and used within 6 months of opening. Keep the medication in its original container, tightly closed, and out of reach of children and pets. Protect from light and moisture. Do not freeze the oral solution. Unused medication should be discarded via a medicine take-back program or according to specific local guidelines.
Disclaimer
This information is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The content has been compiled from various sources believed to be accurate and reliable, but no warranty, expressed or implied, is made regarding its accuracy, reliability, or completeness.
Reviews
“Aripiprazole’s unique pharmacology as a partial agonist has been a valuable tool in my practice, often providing efficacy with a potentially favorable side effect profile regarding metabolic parameters and prolactin elevation compared to some other antipsychotics. However, vigilance for akathisia is paramount.” — Board-Certified Psychiatrist
“The addition of aripiprazole to an SSRI was transformative for several of my patients with treatment-resistant depression. The improvement in energy and motivation was notable, though we monitored closely for any signs of activation or restlessness.” — Clinical Psychologist in a collaborative care model
“As a caregiver, the long-acting injectable form has been crucial for maintaining stability in my family member’s treatment regimen, significantly reducing the stress associated with daily pill management and the risk of missed doses.” — Family Member of a patient
“While effective, the potential for impulse control disorders is a serious consideration that requires proactive discussion and monitoring with every patient initiated on this therapy.” — Psychiatric Nurse Practitioner